ATLANTA, Sept. 16, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's
Neuroscience 2026, the annual meeting of the Society for Neuroscience, will be held November 14–18, 2026 in Washington, DCPresentation Title: Assessing Treatment-Associated Brain Network Changes Following a Novel
ISMRM Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR will be held September 28 – October 1, 2026 at the Universitat Oberta de Catalunya (UOC) in Barcelona, SpainPresentation will report
Company received $7.5 million in gross proceeds from the initial tranche of Series D Convertible Preferred StockAgreement provides for up to $17.5 million in additional funding through subsequent tranche closings to
Potentially Distinct Brain Profile: Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a
Bioequivalence Confirmed: AL001 delivered 101% of total lithium blood exposure and 97% of peak lithium levels vs. standard lithium carbonateSuperior Brain Penetration: AL001 showed numerically higher lithium
Head-to-head studies of AL001 versus marketed lithium carbonate will compare lithium blood and brain/brain-structure pharmacokinetics in bipolar disorder type 1 patientsTopline data expected in third quarter of
Topline data expected in first quarter of 2026Head-to-head studies of AL001 versus a marketed lithium carbonate product was conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy
Session Topic is the Innovation and Current Directions in Military Suicide Prevention, Research, and ProgramsPresentation Title is Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD Subjects Between AL001
During the year ended April 30, 2025, net cash provided by financing activities was $10.4 millionStockholder equity of $4.0 million at April 30, 2025, including $3.9 million of cashIn May 2025, Alzamend dosed the first
ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease
Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects
Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects
Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects
ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of
